PE20210044A1 - Compuestos para el tratamiento de trastornos dependientes de cinasas - Google Patents
Compuestos para el tratamiento de trastornos dependientes de cinasasInfo
- Publication number
- PE20210044A1 PE20210044A1 PE2020001120A PE2020001120A PE20210044A1 PE 20210044 A1 PE20210044 A1 PE 20210044A1 PE 2020001120 A PE2020001120 A PE 2020001120A PE 2020001120 A PE2020001120 A PE 2020001120A PE 20210044 A1 PE20210044 A1 PE 20210044A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- treatment
- kine
- dependent disorders
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describen en la presente compuestos de la Formula I'. Los compuestos de la Formula I' inhiben, regulan y/o modulan el receptor de cinasa, particularmente las vias de transduccion de senales de Axl y Mer relacionadas con los cambios en las actividades celulares mencionados anteriormente, las composiciones que contienen estos compuestos y los metodos para usarlos para el tratamiento de enfermedades y afecciones dependientes de cinasas. La presente invencion tambien proporciona metodos para la confeccion de compuestos mencionados anteriormente, y composiciones que contienen estos compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622626P | 2018-01-26 | 2018-01-26 | |
| US201862622629P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015289 WO2019148036A1 (en) | 2018-01-26 | 2019-01-25 | Compounds for the treatment of kinase-dependent disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210044A1 true PE20210044A1 (es) | 2021-01-08 |
Family
ID=65409542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001120A PE20210044A1 (es) | 2018-01-26 | 2019-01-25 | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11708367B2 (es) |
| EP (1) | EP3743068A1 (es) |
| JP (2) | JP7307733B2 (es) |
| KR (1) | KR20200124678A (es) |
| CN (1) | CN112312909B (es) |
| AU (1) | AU2019212719A1 (es) |
| BR (1) | BR112020015199A2 (es) |
| CA (1) | CA3088127A1 (es) |
| CL (1) | CL2020001930A1 (es) |
| CO (1) | CO2020010467A2 (es) |
| CR (1) | CR20200355A (es) |
| IL (2) | IL302626A (es) |
| MA (1) | MA51672A (es) |
| MX (2) | MX2020007759A (es) |
| PE (1) | PE20210044A1 (es) |
| PH (1) | PH12020551059A1 (es) |
| SA (1) | SA520412488B1 (es) |
| SG (1) | SG11202006945PA (es) |
| UA (1) | UA128348C2 (es) |
| WO (1) | WO2019148036A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019148044A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CA3088198A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| MX2020007759A (es) * | 2018-01-26 | 2020-09-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas. |
| CN112457308B (zh) | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| CN115244041A (zh) * | 2020-03-10 | 2022-10-25 | 南京明德新药研发有限公司 | 乙烯基取代吡啶类化合物 |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP1110953B1 (en) | 1995-03-30 | 2009-10-28 | Pfizer Products Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| RU2006105646A (ru) | 2003-07-23 | 2007-09-10 | Экселиксис, Инк. (Us) | Производные азепина в качестве фармацевтических агентов |
| ATE517091T1 (de) | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
| AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| CN117534755A (zh) | 2005-05-09 | 2024-02-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| RU2008139599A (ru) | 2006-03-07 | 2010-04-20 | Эррэй Биофарма Инк. (Us) | Гетеробициклические производные пиразола и способы их применения |
| MX2011004018A (es) | 2008-10-14 | 2011-06-24 | Ning Xi | Compuestos y metodos de uso. |
| EP2213686A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| EP2214019A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011051271A2 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Prostate tumor markers and methods of use thereof |
| EP2494361B2 (en) | 2009-10-26 | 2019-01-09 | Externautics S.p.A. | Ovary tumor markers and methods of use thereof |
| WO2011051277A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Breast tumor markers and methods of use thereof |
| EP2493916B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
| EP2494351B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Colon and rectal tumor markers and methods of use thereof |
| EP2383578A1 (en) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Tumor marker and methods of use thereof |
| EP2593462B1 (en) * | 2010-07-14 | 2016-09-07 | Betta Pharmaceuticals Co., Ltd. | Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors |
| US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| EP3008086A2 (en) | 2013-06-14 | 2016-04-20 | Externautics S.p.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
| BR112016010224A2 (pt) | 2013-11-05 | 2018-05-02 | Cognate Bioservices, Inc. | combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer. |
| TWI724988B (zh) | 2014-04-25 | 2021-04-21 | 美商艾克塞里克斯公司 | 治療肺腺癌之方法 |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN110437145A (zh) | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| MX2020007759A (es) * | 2018-01-26 | 2020-09-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas. |
-
2019
- 2019-01-25 MX MX2020007759A patent/MX2020007759A/es unknown
- 2019-01-25 BR BR112020015199-8A patent/BR112020015199A2/pt unknown
- 2019-01-25 JP JP2020540750A patent/JP7307733B2/ja active Active
- 2019-01-25 IL IL302626A patent/IL302626A/en unknown
- 2019-01-25 KR KR1020207024577A patent/KR20200124678A/ko not_active Application Discontinuation
- 2019-01-25 EP EP19704968.7A patent/EP3743068A1/en active Pending
- 2019-01-25 PE PE2020001120A patent/PE20210044A1/es unknown
- 2019-01-25 IL IL276028A patent/IL276028B1/en unknown
- 2019-01-25 US US16/964,228 patent/US11708367B2/en active Active
- 2019-01-25 CA CA3088127A patent/CA3088127A1/en active Pending
- 2019-01-25 WO PCT/US2019/015289 patent/WO2019148036A1/en active Application Filing
- 2019-01-25 SG SG11202006945PA patent/SG11202006945PA/en unknown
- 2019-01-25 UA UAA202005478A patent/UA128348C2/uk unknown
- 2019-01-25 CR CR20200355A patent/CR20200355A/es unknown
- 2019-01-25 MA MA051672A patent/MA51672A/fr unknown
- 2019-01-25 AU AU2019212719A patent/AU2019212719A1/en active Pending
- 2019-01-25 CN CN201980021547.0A patent/CN112312909B/zh active Active
-
2020
- 2020-07-09 PH PH12020551059A patent/PH12020551059A1/en unknown
- 2020-07-22 MX MX2022014351A patent/MX2022014351A/es unknown
- 2020-07-23 CL CL2020001930A patent/CL2020001930A1/es unknown
- 2020-07-23 SA SA520412488A patent/SA520412488B1/ar unknown
- 2020-08-25 CO CONC2020/0010467A patent/CO2020010467A2/es unknown
-
2023
- 2023-03-22 JP JP2023045583A patent/JP2023082042A/ja active Pending
- 2023-06-13 US US18/334,113 patent/US20230374024A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019212719A1 (en) | 2020-08-20 |
| MX2020007759A (es) | 2020-09-24 |
| US11708367B2 (en) | 2023-07-25 |
| WO2019148036A1 (en) | 2019-08-01 |
| IL276028B1 (en) | 2024-10-01 |
| UA128348C2 (uk) | 2024-06-19 |
| SG11202006945PA (en) | 2020-08-28 |
| CN112312909B (zh) | 2024-07-02 |
| US20230374024A1 (en) | 2023-11-23 |
| MX2022014351A (es) | 2022-12-13 |
| MA51672A (fr) | 2020-12-02 |
| KR20200124678A (ko) | 2020-11-03 |
| CA3088127A1 (en) | 2019-08-01 |
| US20210040099A1 (en) | 2021-02-11 |
| SA520412488B1 (ar) | 2024-06-23 |
| CR20200355A (es) | 2021-02-22 |
| JP2023082042A (ja) | 2023-06-13 |
| CO2020010467A2 (es) | 2020-10-30 |
| PH12020551059A1 (en) | 2021-05-31 |
| IL276028A (en) | 2020-08-31 |
| EP3743068A1 (en) | 2020-12-02 |
| IL302626A (en) | 2023-07-01 |
| JP2021511359A (ja) | 2021-05-06 |
| CL2020001930A1 (es) | 2020-12-11 |
| JP7307733B2 (ja) | 2023-07-12 |
| CN112312909A (zh) | 2021-02-02 |
| BR112020015199A2 (pt) | 2021-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020010465A2 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| PE20210044A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| CL2019001988A1 (es) | Compuestos químicos como inhibidores de actividad interleuquina-2. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| MX2020004534A (es) | Moduladores de la vía integrada del estrés. | |
| CL2020002511A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CL2021001171A1 (es) | Compuestos de anillo fusionado. | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| CU20200046A7 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| MX2020004538A (es) | Moduladores de la vía de estrés integrada. | |
| CU20180006A7 (es) | Compuestos de indazaol y azaindazol como inhibidores de irak-4 | |
| CL2020001576A1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. | |
| BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| CU20140118A7 (es) | Compuestos de indol e indazol que activan la ampk | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2023002223A1 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| CA3139156A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
| ECSP067096A (es) | Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| EA202092446A1 (ru) | ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34 |